Interleukin-6-induced S100B secretion is inhibited by haloperidol and risperidone

Area of Science:

• Neuroscience
• Neuroinflammation
• Molecular Biology

Background:

• Imbalanced neuroinflammation is linked to brain disorders like schizophrenia and depression.
• Activated glia release pro-inflammatory cytokines, causing neuronal dysfunction.
• Elevated S100B protein levels in schizophrenia suggest glial involvement.

Purpose of the Study:

• To investigate if inflammatory cytokines modulate S100B secretion in glial cells and rat brain.
• To explore the role of mitogen-activated protein kinase (MAPK) pathways in this modulation.
• To examine the effects of antipsychotic drugs on cytokine-induced S100B release.

Main Methods:

• Experiments conducted on C6 glioma cells and Wistar rat hippocampal slices.
• Exposure to key inflammatory cytokines (IL-1β, TNF-α, IL-6, IL-8).
• Assessment of S100B secretion and MAPK pathway activation; drug treatment with haloperidol and risperidone.

Main Results:

• Pro-inflammatory cytokines significantly increased S100B secretion.
• MAPK pathways were involved in mediating this cytokine-induced S100B release.
• Oxidative stress may play a role in the modulation of S100B secretion.
• Haloperidol and risperidone inhibited IL-6-induced S100B secretion in C6 glioma cells.

Conclusions:

• S100B protein is implicated in the inflammatory response in brain diseases, including schizophrenia.
• Cytokine-induced S100B secretion is mediated by MAPK pathways.
• Antipsychotics demonstrate potential to modulate glial inflammatory responses in schizophrenia.